Pfizer Inc. (NYSE:PFE) To Merge Its Off-Patent Business With Mylan (NASDAQ:MYL)

There are reports indicating that Pfizer Inc. (NYSE:PFE) wants to merge its off-patent drug operations in a stock deal with generic drug maker Mylan (NASDAQ:MYL) whose market value is estimated at $9.5 billion. Pfizer to get $12 billion from sale of debt The pharmaceutical company is will spin off its new unit so that it […]

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Excited After FDA Approves Its Epinephrine Injection

Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) rose by more than 50% though that wasn’t the same thing for Mylan N.V. (NASDAQ:MYL) .That was on Thursday after FDA reportedly approved the provider’s Epinephrine injection, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) (PFS) which as a matter of fact happens to be the generic version of […]

Mylan NV (NASDAQ:MYL) Rejects Teva-Takeover, Calls The Bid Undervalued

Global pharmaceutical company Mylan NV (NASDAQ:MYL) chose to reject the unsolicited buyout bid by Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). The decision was made unanimously by the current Board of Directors. Teva Undervalued Mylan The opinionated directors believe that the bid approached by Teva authorities was lackluster, in all regards. The price quoted for Mylan […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Gears To Comply With Regulatory Requirements To Acquire Mylan NV (NASDAQ:MYL)

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Wednesday announced plans to sell some of its operations that are necessary to meet regulatory formalities to purchase its competitor Mylan NV (NASDAQ:MYL). Teva Pharmaceutical has not revealed the details of operations that are put on sale for the possible acquisition. In a bid to reduce pressure for […]

Mylan NV (NASDAQ:MYL) – Immediate Support At $66 Keeps The Bulls In Control

Mylan NV (NASDAQ:MYL) opened up with a big gap of over 9% and managed to end the session with almost all the gains protected after registering a new lifetime high at $74.90. The volume surged to 42 million against the daily average of 15 million only. This spurt in both price and volume was inspired […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Pitches For Mylan For $40 bn

Much to the chagrin of the global pharmaceutical trade, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) made known its intent to acquire its rival, Mylan NV (NASDAQ:MYL) for $40 billion. The deal comes on the back of weeks of speculation that Teva would offer a buyout for Mylan. Touted to be the largest deal of the […]

Appeals Court Takes Side With Mylan NV (NASDAQ:MYL) Over Patent Issue

The previous week proved to be quite eventful for Mylan NV (NASDAQ:MYL). Reports claim that the company had taken the court’s way to protect one of its respiratory medicines that faced a stiff competition from another pharmaceutical company. What’s In For The Company: The U.S. Court of Appeals took company’s side and supported four patents […]

Mylan Inc (NASDAQ:MYL) To Gain From Better Operational Performance Fuelled By Multiple Product Approvals

Boston, MA 10/06/2014 (wallstreetpr) –  Mylan Inc (NASDAQ:MYL) has expressed the confidence that it would be able to gain from better than expected operational performance during the third quarter. The company said that the recent launches and multiple product approvals were supporting its optimism. Boosts Outlook For 3Q Mylan Inc (NASDAQ:MYL) disclosed that the third […]

Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations

Boston, MA 09/16/2014 (wallstreetpr) – In order to sell hepatitis C pill- Sovaldi, in developing countries like South Africa, Vietnam and Honduras, Gilead Sciences, Inc. (NASDAQ:GILD) authorized various drug companies in India. The actual price of hepatitis C pill of the company is $1,000-a-day, which will now be sold at just a dime in the […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) – Nuvigil Patent Infringement Lawsuit Resolved

Boston, MA 06/20/2014 (wallstreetpr) – Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) continues to file a series of patent infringement lawsuits against various company as it seeks to protect its products from generic competition. It goes without saying that some of these cases result in unnecessary expenses, prompting companies to opt for early settlement as it […]

Mylan Inc (NASDAQ:MYL): Will It Create An Entry Into Pain Management?

Boston, MA 06/05/2014 (wallstreetpr) – Mylan Inc (NASDAQ:MYL) settles the patent litigation with Pfizer relating to the generic version of Celebrex. The Company filed the Abbreviated New Drug Application (ANDA) with the FDA for Celebrex capsules. The product primarily uses for the treatment of arthritis and pain management in adults. Legal Settlement Celebrex’s patent will […]

Mylan Inc. (NASDAQ:MYL) Manages license Agreement With Pfizer Inc. (NYSE:PFE) For Generic Version Of Celebrex

Boston, MA 06/04/2014 (wallstreetpr) – Mylan Inc. (NASDAQ:MYL) made an official announcement about its license agreement to sell the generic version of the painkiller capsules Celecoxib, also referred popularly as Celebrex, with Pfizer Inc. (NYSE:PFE). Abbreviated New Drug Application (ANDA) In answer to the aforementioned application made by Mylan Inc. (NASDAQ:MYL) to the US FDA, […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA): The Time To Sell

Boston, MA 06/03/2014 (wallstreetpr) – Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is trading near its 52 week high. Seeing the present conditions linked with Copaxone, it is wise to sell the stock or have some cushion by buying the put options. Goldman has warned of a sell off on Teva due to the problems associated […]

Competition Stricken Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) May Look For India Deal Despite Denial

Boston, MA 05/23/2014 (wallstreetpr) – The Israel-based drug company Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has taken several doses of its own medicine in recent times. The company that thrives in developing and marketing generic drugs has in recent times until last week tried to stop competitors from developing a copycat of its bestselling Copaxone […]

Valero Energy Corporation (NYSE:VLO): Dark Days have Overshadowed

Boston, MA 04/09/2014 (wallstreetpr) – Wall Street had seen dramatic changes in the very recent days as most of the investors had escaped from the stock market on Monday with an intensified sell-off. The NYSE also had ended with a dark closing bell on Monday with three major companies finishing-off the day on a worse note. […]